anti-CD19 CAR T-cell therapy FLAG-tagged (ProMab Biotechnologies/Forevertek Biotechnology)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-CD19 CAR T-cell therapy FLAG-tagged (ProMab Biotechnologies/Forevertek Biotechnology)
Drug Alias NameCD19-FLAG CAR T-cell therapy (ProMab Biotechnologies/Forevertek Biotechnology)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-CellNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesProMab Biotechnologies Inc
China Registration ClassN/A

Develop Information

Active CompaniesProMab Biotechnologies IncForevertek Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A